<DOC>
	<DOC>NCT00325455</DOC>
	<brief_summary>To assess the cholesterol changing effects of MK0859 in patients with primary hypercholesterolemia or mixed dyslipidemia.</brief_summary>
	<brief_title>MK0859 Dose-Ranging Study (0859-003)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type V</mesh_term>
	<mesh_term>Anacetrapib</mesh_term>
	<criteria>Eligible patients will be men and women of nonchild bearing potential, 18 through 75 years of age diagnosed with high cholesterol Patients with CHD or CHDequivalent disease (except diabetes) Diabetics on statins</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>